Welcome to our dedicated page for Kalvista Pharm SEC filings (Ticker: KALV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
KalVista Pharmaceuticals SEC filings document 8-K disclosures for a commercial-stage pharmaceutical company focused on oral rare-disease therapies. The filings cover results of operations and financial condition, Regulation FD materials, product-revenue updates tied to EKTERLY, and the company’s Nasdaq-listed common stock.
The filing record also includes governance and compensation disclosures, board committee changes, executive appointments, material definitive agreements, and capital-structure actions. Financing disclosures include the completed sale of 3.250% convertible senior notes due 2031, while other reports describe exhibit filings, furnished press releases, Inline XBRL cover data, and formal disclosure treatment under the Exchange Act.
KalVista Pharmaceuticals chief development officer Christopher Yea reported routine equity compensation activity. He exercised 3,750 restricted stock units (RSUs), receiving the same number of common shares for no cash cost. Following this, he sold 2,358 common shares at $26.7844 per share.
According to the footnotes, this sale was a non-discretionary “sell to cover” transaction to fund tax withholding tied to the RSU vesting, rather than an elective sale. After these transactions, Yea directly holds 228,759 common shares and 41,250 RSUs that continue to vest quarterly, indicating he retains nearly all of his equity exposure.
KalVista Pharmaceuticals Chief Medical Officer Paul K. Audhya reported routine equity compensation-related transactions. On May 21, 2026, he exercised 6,250 restricted stock units (RSUs), receiving 6,250 shares of Common Stock at $0.00 per share upon settlement.
On May 22, 2026, he sold 2,685 Common Stock shares at an average price of $26.7844 per share solely to cover tax withholding obligations through a "sell to cover" transaction, which the filing states was not a discretionary sale. After these transactions, he directly owned 147,499 Common Stock shares and 68,750 RSUs representing contingent rights to receive an equal number of shares over time, subject to vesting.
KalVista Pharmaceuticals Chief Financial Officer Brian Piekos reported routine equity compensation activity and a tax-related share sale. On May 21, 2026, 5,000 restricted stock units converted into 5,000 shares of common stock for no cash consideration. On May 22, 2026, 1,489 of those shares were sold at $26.7844 per share solely to cover tax withholding obligations under a “sell to cover” arrangement, which the company states was not a discretionary transaction. After these events, Piekos directly held 21,661 shares of common stock, and his reported restricted stock unit balance was 55,000 units.
KalVista Pharmaceuticals received an Amendment No. 8 to a Schedule 13D from a group of Frazier Life Sciences funds and related entities updating their ownership information. Frazier Life Sciences Public Fund, L.P. directly holds 1,249,165 shares of KalVista common stock, representing 2.3% of the outstanding shares based on 53,240,888 shares outstanding as of May 7, 2026. Frazier Life Sciences X, L.P. holds 427,983 shares (0.8%), Frazier Life Sciences XI, L.P. holds 145,592 shares (0.3%), and Frazier Life Sciences XII, L.P. holds 6,563 shares (0.0%). The filing clarifies that certain entities act as general partners to these funds and that James N. Topper and Patrick J. Heron share voting and investment power only over the FLS X shares, with other funds managed by investment committees where individual members are not attributed beneficial ownership.
KalVista Pharmaceuticals chief development officer Christopher Yea reported routine equity compensation activity. On May 17, 2026, 1,774 restricted stock units vested and were converted into the same number of common shares for no cash consideration. On May 18, 2026, 1,108 common shares were sold at $26.76 per share solely to cover tax withholding obligations through a “sell to cover” arrangement, described as a non-discretionary transaction. After these transactions, Yea directly holds 227,367 shares of KalVista common stock.
KalVista Pharmaceuticals, Inc. Chief Medical Officer Paul K. Audhya reported routine equity compensation activity involving restricted stock units (RSUs) and a small related sale. On May 17, 2026, he exercised RSUs covering 2,419 shares of common stock at $0.00 per share, converting all of those RSUs into common shares.
On May 18, 2026, he sold 1,032 shares of common stock at an average price of $26.76 per share. A footnote explains this was a "sell to cover" transaction to satisfy tax withholding obligations tied to the RSU vesting, and is described as not a discretionary trade. Following these transactions, he directly holds 143,934 shares of KalVista common stock.
KalVista Pharmaceuticals CEO Benjamin L. Palleiko reported routine equity transactions tied to RSU vesting. On May 17, he exercised 2,419 restricted stock units, receiving the same number of common shares at no cost. On May 18, he sold 1,129 common shares at $26.76 per share to cover tax withholding obligations, according to the footnotes, which state this was a non-discretionary “sell to cover” transaction. After these moves, he directly holds 467,665 common shares.
Point72 Asset Management, Point72 Capital Advisors Inc. and Steven A. Cohen report beneficial ownership of 2,136,940 shares of KalVista Pharmaceuticals common stock, representing 4.2% of the class as of the close of business on March 31, 2026, pursuant to Amendment No. 2 to a Schedule 13G/A.
The filing states the shares are held by an investment fund managed by Point72 Asset Management, with shared voting and dispositive power reported. The reporting persons state they directly own no shares and that Point72 Asset Management maintains investment and voting power for the fund.
KalVista Pharmaceuticals reported its first meaningful commercial quarter as EKTERLY sales drove total revenue of $40.9M for the three months ended March 31, 2026, up from zero a year earlier. Product revenue reached $39.2M, largely from U.S., Germany and Japan launches, while partnership revenue contributed $1.7M.
Operating expenses rose to $64.3M, mainly from higher commercial and administrative spending, but the net loss narrowed to $23.5M (basic and diluted loss per share $0.43) from $51.8M in the prior-year quarter. KalVista ended the period with cash, cash equivalents and marketable securities totaling $285.0M, which management believes is sufficient to fund operations for at least twelve months.
Separately, KalVista agreed to be acquired by Chiesi through a tender offer at $27.00 per share in cash, followed by a merger that would take the company private, subject to a majority tender, regulatory clearances and other customary conditions. If the merger is not completed under certain circumstances, KalVista could owe Chiesi a $66.4M termination fee.
KalVista Pharmaceuticals, Inc. recommends that stockholders tender their shares to Purchaser in a cash tender offer of $27.00 per share. If the Offer is consummated and accepted, Purchaser will merge into the company and KalVista will become a wholly owned subsidiary of Parent.
As of May 6, 2026, there were 53,240,888 Shares outstanding. The Offer’s initial expiration is one minute after 11:59 p.m. Eastern Time on June 10, 2026. The Merger Agreement includes a $66.4 million termination fee and details treatment of outstanding options, RSUs, warrants, ESPP rights, executive transaction bonuses, and estimated golden‑parachute payments.